Twenty-four–hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination

Konstas, Anastasios G. P.; Papapanos, Panayiotis; Tersis, Ioannis; Houliara, Dimitra; Stewart, William C.

doi:10.1016/s0161-6420(03)00404-4

Cited by 60 publications

(42 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several previous studies have indicated that latanoprost dosed in the evening provided better daytime pressures than when dosed in the morning, which provides better night-time pressures. 17,20,21 Night-time dosing of the latanoprost based fixed combination could have improved the daytime pressure with the latanoprost based fixed combination.…”

Section: Discussionmentioning

confidence: 99%

Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%

Konstas

Kozobolis

Lallos

et al. 2004

Eye

View full text Add to dashboard Cite

Purpose The diurnal efficacy and safety of the fixed combinations of latanoprost/timolol given once daily vs dorzolamide/timolol given twice daily in primary open-angle glaucoma or ocular hypertensive patients. Design A double-masked, two-centre, crossover comparison. Results In 33 patients, the mean diurnal IOP (0800-2000, measured every 2 h) for latanoprost/ timolol fixed combination was 17.372.2 mmHg and for dorzolamide/timolol, the fixed combination was 17.072.0 mmHg (P ¼ 0.36). Additionally, there was no statistical difference for individual time points following a Bonferroni correction. A bitter taste was found more frequently with the dorzolamide/timolol fixed combination (n ¼ 6) than the latanoprost/ timolol fixed combination (n ¼ 0) (P ¼ 0.040), while the latanoprost/timolol fixed combination demonstrated more conjunctival hyperaemia (n ¼ 9) than the dorzolamide/timolol fixed combination (n ¼ 2) (P ¼ 0.045). One patient was discontinued early from the dorzolamide/ timolol fixed combination due to elevated IOP. Conclusion This study suggests that the daytime diurnal IOP is not statistically different between the dorzolamide/timolol fixed combination and latanoprost/timolol fixed combination in primary open-angle glaucoma and ocular hypertensive patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%

Konstas

Kozobolis

Lallos

et al. 2004

Eye

View full text Add to dashboard Cite

show abstract

“…[6][7][8][9][10][11][12] All patients signed an Institutional Review Board approved informed consent form before enrollment. Previously treated patients underwent an untreated washout period comprising 4 weeks for brimonidine, or dorzolamide; 5 weeks for beta-blockers or the dorzolamide/timolol fixed combination; and 6 weeks for prostaglandin analogues.…”

Section: Methodsmentioning

confidence: 99%

Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components

Konstas

Katsimpris

Kaltsos

et al. 2007

Eye

View full text Add to dashboard Cite

Purpose To evaluate the 24-h intraocular pressure (IOP) control of brimonidine/timolol fixed combination (BTFC) versus the unfixed combination of its individual components, each dosed twice daily, in patients with primary open-angle glaucoma or ocular hypertension. Methods An observer-masked, randomized, crossover, active-controlled, two-centre comparison. Following a 6-week medicine-free period, patients were randomized to BTFC or to the unfixed combination of brimonidine and timolol for 3 months. Patients then were crossed over to the opposite treatment for another 3 months. At the end of the medicinefree period, and each treatment period, patients underwent 24-h IOP measurements at 0600, 1000, 1400, 1800, 2200, and 0200 hours. Results Twenty-eight patients completed this study. Both BTFC and the unfixed components showed a significant IOP reduction from untreated baseline (Po0.0001), and were statistically equal when compared directly, for each individual time point and for the 24-h IOP curve (P40.05). The mean 24-h IOP was 24.671.9 for baseline, 19.271.9 for BTFC, and 19.271.6 mmHg for the unfixed components (P ¼ 1.0). Four patients were discontinued due to side effects. The most common ocular adverse event was ocular hyperaemia (n ¼ 3 with BTFC and n ¼ 5 with the unfixed components, P ¼ 0.7) and systemic adverse events were rare. Conclusion This study suggests that both BTFC and the unfixed components of brimonidine and timolol provide a significant 24-h IOP reduction from untreated baseline, and statistically equal control when compared directly, at each time point and for the 24-h pressure curve.

show abstract

“…It is conceivable that these aspects of the design could have influenced the results. A recent small, 6-week, cross-over study that was observer-masked (but not patientmasked), and that did not select patients on the basis of their previous response to b-blocker therapy, found that the dorzolamide/timolol combination lowered IOP more effectively than latanoprost by a small but statistically significant amount (Konstas et al 2003). In this paper we report results from two large observer-masked and patient-masked randomized clinical trials that compared the efficacy and tolerability of the two treatments in patients who were not preselected on the basis of their response to existing therapy.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT™) versus latanoprost 0.005% (XALATAN™) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials

Fechtner

Airaksinen

Getson

et al. 2003

Acta Ophthalmologica Scandinavica

View full text Add to dashboard Cite

ABSTRACT.Purpose: To compare the efficacy of the fixed dorzolamide 2%/timolol 0.5% combination (COSOPT TM ) versus latanoprost 0.005% (XALATAN TM ). Methods: Two 3-month, parallel group, randomized, observer-masked and patient-masked, multicentre, clinical trials were performed in patients with ocular hypertension or open-angle glaucoma. Study 1 (n ¼ 256) was conducted in the United States and Study 2 (n ¼ 288) was conducted in Europe/Israel. Patients could be included whether or not they were currently taking ocular hypotensive therapy, and regardless of the effectiveness of any previous therapy. Patients were washed out from their usual ocular hypotensive medications and then those with a baseline intraocular pressure (IOP) !24 mmHg were randomized to either the dorzolamide/timolol combination eye drops twice daily or latanoprost eye drops once daily in both eyes. Efficacy was assessed by daytime diurnal IOP (the mean of measurements made at 0800, 1000, 1400 and 1600 h). Results: At baseline, the mean daytime diurnal IOP was 26.1 mmHg in the dorzolamide/timolol combination group versus 25.6 mmHg in the latanoprost group in Study 1, and 25.3 mmHg in the dorzolamide/timolol combination group versus 24.7 mmHg in the latanoprost group in Study 2. After 3 months, the mean daytime diurnal IOP was 18.9 mmHg for the dorzolamide/timolol combination versus 18.4 mmHg for latanoprost in Study 1, and 17.4 mmHg for the dorzolamide/timolol combination versus 17.5 mmHg for latanoprost in Study 2. The difference between treatments in mean IOP change at 3 months was À0.04 mmHg [95% confidence interval (CI) À0.85, 0.77] in Study 1, and À0.57 mmHg (95% CI À1.31, 0.16) in Study 2. The probability that the true ACTA OPHTHALMOLOGICA SCANDINAVICA 2004 42 difference lay between À1.5 and 1.5 mmHg, the predefined bounds for equivalance, was >0.950 in both studies. Both treatments were well tolerated over 3 months, although ocular stinging occurred more frequently with the dorzolamide/ timolol combination. Conclusion: The dorzolamide/timolol combination and latanoprost were equally effective at lowering IOP.

show abstract

Twenty-four–hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination

Cited by 60 publications

References 24 publications

Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%

Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%

Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components

Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT™) versus latanoprost 0.005% (XALATAN™) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials

Contact Info

Product

Resources

About